RCS - PureTech Health PLC - PureTech to Present at the JP Morgan Conference

Puretech HealthAnnouncement

08/01/2025 12:01

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250108:nRSH4767Sa&default-theme=true

RNS Number : 4767S  PureTech Health PLC  08 January 2025

8 January 2025

PureTech Health plc

 

PureTech to Present at 43(rd) Annual J.P. Morgan Healthcare Conference

 

PureTech Health plc (https://puretechhealth.com/) (Nasdaq: PRTC, LSE: PRTC)
("PureTech" or the "Company"), a clinical-stage biotherapeutics company
dedicated to changing the lives of patients with devastating diseases, today
announced that Bharatt Chowrira, PhD, JD, Chief Executive Officer, will
present at the 43(rd) annual J.P. Morgan Healthcare Conference on Wednesday,
January 15, 2025, at 11:15am PST / 2:15pm EST. A webcast of the presentation
will be available at https://investors.puretechhealth.com
(https://investors.puretechhealth.com) .

 

About PureTech Health

PureTech is a clinical-stage biotherapeutics company dedicated to giving
life to new classes of medicine to change the lives of patients with
devastating diseases. The Company has created a broad and deep pipeline
through its experienced research and development team and its extensive
network of scientists, clinicians and industry leaders that is being advanced
both internally and through its Founded Entities. PureTech's R&D
engine has resulted in the development of 29 therapeutics and therapeutic
candidates, including three that have been approved by the U.S. Food and
Drug Administration. A number of these programs are being advanced
by PureTech or its Founded Entities in various indications and stages of
clinical development, including registration-enabling studies. All of the
underlying programs and platforms that resulted in this pipeline of
therapeutic candidates were initially identified or discovered and then
advanced by the PureTech team through key validation points.

 

For more information, visit www.puretechhealth.com
(http://www.puretechhealth.com/)  or connect with us on X (formerly Twitter)
@puretechh.

 

Cautionary Note Regarding Forward-Looking Statements

This press release contains statements that are or may be forward-looking
statements within the meaning of the Private Securities Litigation Reform Act
of 1995. All statements contained in this press release that do not relate to
matters of historical fact should be considered forward-looking statements,
including without limitation those related to our upcoming presentation at the
43(rd) Annual J.P. Morgan Healthcare Conference and our future prospects,
developments and strategies. The forward-looking statements are based on
current expectations and are subject to known and unknown risks, uncertainties
and other important factors that could cause actual results, performance and
achievements to differ materially from current expectations, including, but
not limited to, those risks, uncertainties and other important factors
described under the caption "Risk Factors" in our Annual Report on Form 20-F
for the year ended December 31, 2023, filed with the SEC and in our other
regulatory filings. These forward-looking statements are based on assumptions
regarding the present and future business strategies of the Company and the
environment in which it will operate in the future. Each forward-looking
statement speaks only as at the date of this press release. Except as required
by law and regulatory requirements, we disclaim any obligation to update or
revise these forward-looking statements, whether as a result of new
information, future events or otherwise.

 

Contact:

PureTech

Public Relations

publicrelations@puretechhealth.com (mailto:publicrelations@puretechhealth.com)
 

Investor Relations

IR@puretechhealth.com (mailto:IR@puretechhealth.com)

 

UK/EU Media

Ben Atwell, Rob Winder

+44 (0) 20 3727 1000

puretech@fticonsulting.com (mailto:puretech@fticonsulting.com)   

 

US Media

Justin Chen

+1-609-578-7230

jchen@tenbridgecommunications.com (mailto:jchen@tenbridgecommunications.com)
    

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRABRGDBIXGDGUR